Machine Learning as a Support for the Diagnosis of Type 2 Diabetes
International Journal of Molecular Sciences · 05.04.2023 · 24 (7) · 6775
DOI: 10.3390/ijms24076775 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.04.2023. Verfasst von Antonio Agliata und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Aziendali, Management and Innovation Systems, Università degli Studi di Salerno, 84084 Fisciano, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIR01_00017—“CNRBiOmics Centro Nazionale di Ricerca in Bioinformatica per le Scienze Omiche.
Themen: Künstliche Intelligenz in der Pflege, Diabetes mellitus
Abstract (Originalsprache)
Diabetes is a chronic, metabolic disease characterized by high blood sugar levels. Among the main types of diabetes, type 2 is the most common. Early diagnosis and treatment can prevent or delay the onset of complications. Previous studies examined the application of machine learning techniques for prediction of the pathology, and here an artificial neural network shows very promising results as a possible valuable aid in the management and prevention of diabetes. Additionally, its superior ability for long-term predictions makes it an ideal choice for this field of study. We utilized machine learning methods to uncover previously undiscovered associations between an individual’s health status and the development of type 2 diabetes, with the goal of accurately predicting its onset or determining the individual’s risk level. Our study employed a binary classifier, trained on scratch, to identify potential nonlinear relationships between the onset of type 2 diabetes and a set of parameters obtained from patient measurements. Three datasets were utilized, i.e., the National Center for Health Statistics’ (NHANES) biennial survey, MIMIC-III and MIMIC-IV. These datasets were then combined to create a single dataset with the same number of individuals with and without type 2 diabetes. Since the dataset was balanced, the primary evaluation metric for the model was accuracy. The outcomes of this study were encouraging, with the model achieving accuracy levels of up to 86% and a ROC AUC value of 0.934. Further investigation is needed to improve the reliability of the model by considering multiple measurements from the same patient over time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dipartimento di Scienze Aziendali, Management and Innovation Systems, Università degli Studi di Salerno, 84084 Fisciano, Italy.
- BC Soft, Centro Direzionale, Via Taddeo da Sessa Isola F10, 80143 Napoli, Italy.
- National Research Council, Institute of Food Science, Via Roma 64, 83100 Avellino, Italy.
ORCID-Profile: Deborah Giordano, Francesco Bardozzo, Salvatore Bottiglieri, Angelo Facchiano, Roberto Tagliaferri
Förderung
- CIR01_00017—“CNRBiOmics Centro Nazionale di Ricerca in Bioinformatica per le Scienze Omiche
Zitieren
APA
Agliata, A., Giordano, D., Bardozzo, F., Bottiglieri, S., Facchiano, A., & Tagliaferri, R. (2023). Machine Learning as a Support for the Diagnosis of Type 2 Diabetes. International Journal of Molecular Sciences, 24(7), 6775. https://doi.org/10.3390/ijms24076775
Vancouver
Agliata A, Giordano D, Bardozzo F, Bottiglieri S, Facchiano A, Tagliaferri R. Machine Learning as a Support for the Diagnosis of Type 2 Diabetes. International Journal of Molecular Sciences. 2023;24(7):6775. doi:10.3390/ijms24076775
BibTeX
@article{Agliata2023,
author = {Agliata, Antonio and Giordano, Deborah and Bardozzo, Francesco and Bottiglieri, Salvatore and Facchiano, Angelo and Tagliaferri, Roberto},
title = {Machine Learning as a Support for the Diagnosis of Type 2 Diabetes},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {7},
pages = {6775},
doi = {10.3390/ijms24076775}
}
EUVIMED